CHF 72.00
In stock
SYN-3024-M0011 mgCHF 72.00
SYN-3024-M0055 mgCHF 108.00
SYN-3024-M01010 mgCHF 132.00
SYN-3024-M05050 mgCHF 461.00
SYN-3024-M100100 mgCHF 814.00
More Information
Product Details
Synonyms GAR 936; Glycylcycline; Tygacil; WAY-GAR 936
Product Type Chemical
Formula C29H39N5O8
MW 585.7
CAS 220620-09-7
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: Bacterial Ribosime (30S) | Kinase Group: | Substrate: N/A

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Tigecycline is a glycylcycline antibiotic, a new class of antibiotics derived from tetracycline, with broad-spectrum activity. These tetracycline analogues are specifically designed to overcome two common mechanisms of tetracycline resistance, namely resistance mediated by acquired efflux pumps and/or ribosomal protection. Glycylcycline antibiotics have a similar mechanism of action as tetracycline antibiotics. Both classes of antibiotics inhibit protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracycline and imparts certain microbiologic properties to tigecycline. Accordingly, tigecycline has demonstrated in vitro and in vivo activity against a broad spectrum of bacterial pathogens. However, the glycylcyclines appear to bind more effectively than the tetracyclines. Tigecycline was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumanii.
Product References
  1. The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin-Structure Infections: Results of 2 Double-Blind Phase 3 Comparison Studies with Vancomycin-Aztreonam: E.J. Ellis-Grosse, et al.; Clin. Infect. Dis. 41, 341 (2005)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.